New stem cell research points to early indicators of schizophrenia
Salk scientists show fundamental differences in early neurons from patients with schizophrenia, supporting the theory that risk for the disease may begin in the womb
LA JOLLA—Using new stem cell technology, scientists at the Salk Institute have shown that neurons generated from the skin cells of people with schizophrenia behave strangely in early developmental stages, providing a hint as to ways to detect and potentially treat the disease early.
The findings of the study, published online in April's Molecular Psychiatry, support the theory that the neurological dysfunction that eventually causes schizophrenia may begin in the brains of babies still in the womb.
"This study aims to investigate the earliest detectable changes in the brain that lead to schizophrenia," says Fred H. Gage, Salk professor of genetics. "We were surprised at how early in the developmental process that defects in neural function could be detected."
These images show the movement of patient-derived neural progenitor cells from a sphere of neurons in a migration assay. How far and quickly the neurons move indicates whether they may behave atypically in the brain.
Image: Courtesy of the Salk Institute for Biological Studies
Currently, over 1.1 percent of the world's population has schizophrenia, with an estimated three million cases in the United States alone. The economic cost is high: in 2002, Americans spent nearly $63 billion on treatment and managing disability. The emotional cost is higher still: 10 percent of those with schizophrenia are driven to commit suicide by the burden of coping with the disease.
Although schizophrenia is a devastating disease, scientists still know very little about its underlying causes, and it is still unknown which cells in the brain are affected and how. Previously, scientists had only been able to study schizophrenia by examining the brains of patients after death, but age, stress, medication or drug abuse had often altered or damaged the brains of these patients, making it difficult to pinpoint the disease's origins.
The Salk scientists were able to avoid this hurdle by using stem cell technologies. They took skin cells from patients, coaxed the cells to revert back to an earlier stem cell form and then prompted them to grow into very early-stage neurons (dubbed neural progenitor cells or NPCs). These NPCs are similar to the cells in the brain of a developing fetus.
The researchers generated NPCs from the skin cells of four patients with schizophrenia and six people without the disease. They tested the cells in two types of assays: in one test, they looked at how far the cells moved and interacted with particular surfaces; in the other test, they looked at stress in the cells by imaging mitochondria, which are tiny organelles that generate energy for the cells.
On both tests, the Salk team found that NPCs from people with schizophrenia differed in significant ways from those taken from unaffected people.
In particular, cells predisposed to schizophrenia showed unusual activity in two major classes of proteins: those involved in adhesion and connectivity, and those involved in oxidative stress. Neural cells from patients with schizophrenia tended to have aberrant migration (which may result in the poor connectivity seen later in the brain) and increased levels of oxidative stress (which can lead to cell death).
These findings are consistent with a prevailing theory that events occurring during pregnancy can contribute to schizophrenia, even though the disease doesn't manifest until early adulthood. Past studies suggest that mothers who experience infection, malnutrition or extreme stress during pregnancy are at a higher risk of having children with schizophrenia. The reason for this is unknown, but both genetic and environmental factors likely play a role.
"The study hints that there may be opportunities to create diagnostic tests for schizophrenia at an early stage," says Gage, who holds the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Disease.
Kristen Brennand, the first author of the paper and assistant professor at Icahn School of Medicine at Mount Sinai, said the researchers were surprised that the skin-derived neurons remained in such an early stage of development. "We realized they weren't mature neurons but only as old as neurons in the first trimester," Brennand says. "So we weren't studying schizophrenia but the things that go wrong a long time before patients actually get sick."
Interestingly, the study also found that antipsychotic medication such as clozapine and loxapine did not improve migration in NPCs (in particular, loxapine actually worsened migration in these cells).
"That was an experiment that gave the opposite results from what we were expecting," says Brennand. "Though in hindsight, using drugs that treat symptoms might not be helpful in trying to prevent the disease."
The next steps to this work will be to increase the sample size to a broader range of patients and to look at hundreds or thousands of patient samples, says Brennand.
Contributors to this work include Yongsung Kim, Ngoc Tran, Anthony Simone, Hyung Joon Kim, and Ian Ladran at the Salk Institute; Jeffrey Savas and John Yates at the Scripps Research Institute; Kazue Hashimoto-Torii and Pasko Rakic at Yale University; Kristin Beaumont and Milan Mrksich at Northwestern University; Aaron Topol, Mohammed Abdelrahim, Bridget Matikainen-Ankne, Gang Fang and Bin Zhang at Icahn School of Medicine at Mount Sinai; and Shih-hui Chao at Arizona State University Tempe.
The Gage Laboratory is partially funded by the California Institute of Regenerative Medicine (CIRM), the G Harold & Leila Y Mathers Foundation, the JPB Foundation, the Leona M and Harry B Helmsley Charitable Trust, Annette Merle-Smith, and Robert and Mary Jane Engman. The Brennand Laboratory is partially funded by NARSAD, NIMH and the New York Stem Cell Foundation.
About the Salk Institute for Biological Studies:
The Salk Institute for Biological Studies is one of the world's preeminent basic research institutions, where internationally renowned faculty probes fundamental life science questions in a unique, collaborative, and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer's, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.
Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark.